Medicine

One CRISPR infusion kept blood fats low in monkeys for three years

Verve Therapeutics reports that a single dose of a base editor cut ANGPTL3 protein by about 94%, with triglycerides 43% lower three years later.

By Letizia Giugliano
3 min read

ShareLinkedInFacebookX

One CRISPR infusion kept blood fats low in monkeys for three years
Photo: Europeana / Unsplash

Ten monkeys received one infusion of an experimental CRISPR base editor and were followed for three years. Their levels of ANGPTL3, a liver protein that slows the clearance of fats from the blood, stayed about 94% below where they started. The results, published in Nature by researchers at Verve Therapeutics and collaborating institutions, point to a DNA-level alternative to daily lipid-lowering drugs.

A single infusion, and three years of lower triglycerides

The gene-editing invention targets ANGPTL3, a gene that codes for a liver-secreted protein which slows the clearance of fats from the blood. In the durability study, monkeys with normal lipid levels received either one infusion of the therapy or a control formulation, and ten animals in the active group were followed for three years, Medical Xpress reports.

At follow-up, ANGPTL3 protein averaged about 94% below pretreatment levels. Triglycerides averaged 43% lower, while LDL cholesterol fell by a more modest 13%. Liver samples taken at seven weeks and at three years showed similar protein levels, which is the part that matters for a one-shot therapy: the edit did not fade.

Read also on The Patent: GAO Warns USPTO Backlog Targets Risk Failure Under Staff Strain

The gene was already a validated target. Evinacumab, an antibody drug for a severe inherited cholesterol disorder, blocks the same protein but needs infusions every four weeks. Gene editing aims instead to stop the liver from making the protein at all.

“alleviate the burdens of chronic lipid-lowering treatment”

— The study authors, writing in Nature

How a base editor switches off ANGPTL3

The researchers packaged RNA instructions for a CRISPR base editor and an RNA guide inside tiny fat-based particles. The guide takes the editor to ANGPTL3, where changing one DNA letter disrupts the instructions for building the protein. The delivery components and the RNA are largely cleared after treatment, and the DNA change is designed to stay.

The work comes from Verve Therapeutics, an Eli Lilly subsidiary that funded the study, with collaborating institutions. Most authors are company employees, and several hold Lilly shares or are named on related patent applications and other intellectual property, a set of interests the paper discloses. The study, led by Taiji Mizoguchi, appears in Nature under DOI 10.1038/s41586-026-11233-9.

A sugar tag that opens a second door into liver cells

Fat-based particles normally depend on LDL receptors to get into liver cells. That is a problem for people with homozygous familial hypercholesterolemia, a rare inherited disorder in which those receptors are severely deficient: the delivery vehicle loses its entrance at the same time as the disease removes the body's cholesterol clearance.

The team's particles carry GalNAc, a sugar-based targeting molecule that enters liver cells through a different receptor. In four monkeys whose LDL-receptor gene had been disrupted, the ANGPTL3 treatment cut average LDL cholesterol from 458 to 247 milligrams per deciliter after 35 days, a 46% drop. The researchers note that this shorter experiment did not establish years of cholesterol lowering in animals lacking the receptor.

Liver enzymes rose, then returned to baseline

Liver enzymes went up temporarily in the treated monkeys and came back to baseline within two weeks. Follow-up tests and tissue examinations found no evidence of lasting liver toxicity, according to the report.

In cultured human liver cells, the human version of the treatment produced no detectable unintended editing at roughly 3,000 candidate DNA sites. The authors are careful about the limit of that check: a targeted search of this kind cannot rule out every possible unwanted change. Independent confirmation will have to come from patients.

VERVE-201 enters a phase 1b trial

The human version of the therapy, VERVE-201, is being tested in a phase 1b trial in people whose blood lipids remain inadequately controlled. The stated hope is to "alleviate the burdens of chronic lipid-lowering treatment," the researchers write in Nature.

Whether a lasting edit can deliver that benefit safely is now a question for the human trials. The monkey data cover three years of durability and a short-term liver safety signal; they say nothing yet about how a edited liver behaves over a human lifetime, or about who would be eligible for a one-time treatment rather than a pill — an innovation whose real test is only beginning.

AI-assisted article